Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

(Reuters) -British drugmaker GSK expects annual sales and profit to be towards the top of its forecast range, after ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), its partner for the Comirnaty COVID-19 vaccine, made legal submissions to London's Court of Appeal on Thursday seeking to overturn a prior court ruling ...

Pfizer’s pipeline remains a crucial component of its long-term growth strategy. The company has made significant strides in key therapeutic areas, particularly in oncology and obesity treatments.

Pfizer Inc. (NYSE: PFE), a global pharmaceutical giant with a market capitalization of $138.21 billion, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Pfizer, BioNTech challenge Moderna’s COVID vaccine patent win in U.K. Jul. 10, 2025 8:08 AM ET Pfizer Inc. (PFE) Stock, MRNA Stock, BNTX Stock By: Dulan Lokuwithana, SA News Editor 1 Comment ...